XML 69 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
Investments in Joint Ventures and Related Party Transactions (Tables)
9 Months Ended
Sep. 30, 2014
Equity Method Investments and Joint Ventures [Abstract]  
Summary of carrying amounts of assets and fair value of liabilities included in Condensed Consolidated Balance Sheet and maximum loss exposure in VIE
The following table summarizes the carrying amounts of the assets and the fair value of the liabilities included in the Company’s condensed consolidated balance sheet and the maximum loss exposure related to the Company’s interest in its unconsolidated VIE (the Solazyme Bunge JV) as of September 30, 2014 (in thousands):
 
Assets
 
Liabilities
 
 
VIE
Accounts
Receivable
 
Unbilled
Revenues
 
Investment in
Unconsolidated
Joint Ventures
 
Loan
Guarantee
 
Maximum
Exposure
to Loss (1)
Solazyme Bunge JV
$
4,083

 
$
5,287

 
$
41,896

 
$

 
$
66,847

 
(1)
Includes maximum exposure to loss attributable to the Company’s bank guarantee required to be provided for the Solazyme Bunge JV of R$35.4 million (approximately $14.5 million based on the exchange rate at September 30, 2014) and non-cancelable purchase obligations of R$2.6 million (approximately $1.1 million based on the exchange rate at September 30, 2014).
Summarized financial information on Solazyme Bunge JV's Balance Sheets and Income Statements
Summarized information on the Solazyme Bunge JV’s balance sheets and income statements as of June 30, 2014 and December 31, 2013 and for the three and nine months ended September 30, 2014 and 2013, respectively, was as follows (in thousands):
 
September 30,
2014
 
December 31,
2013
Current assets
$
3,974

 
$
9,872

Noncurrent assets
197,746

 
127,346

Total assets
$
201,720

 
$
137,218

Current liabilities
40,853

 
20,798

Noncurrent liabilities
90,737

 
90,933

JV's partners' capital, net
70,130

 
25,487

Total liabilities and partners' capital, net
$
201,720

 
$
137,218

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2014
 
2013
 
2014
 
2013
Net sales
$
540

 
$

 
$
540

 
$

Net losses
$
10,992

 
$
4,289

 
$
23,822

 
$
7,350